Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting      — Systemic disease control achieved in heavily pre-treated liver cancer patients      — 83% DCR; median PFS of 9.2 months; median OS of 22.5 months; half of patients undergoing response...